May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Comparative Efficacy of Topical Mupirocin With Ciprofloxacin, Gatifloxacin and Vancomycin in the Treatment of Experimental Ciprofloxacin– and Methicillin–Resistant Staphylococcus Aureus Keratitis
Author Affiliations & Notes
  • M.–K. Kim
    Ophthalmology, Seoul, Seoul, Republic of Korea
    Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute, Seoul, Republic of Korea
  • P. Botelho
    Ocular Microbiology and Immunology Laboratory, Wilmer Eye Institute, Baltimore, MD
  • C. Zhang
    Ocular Microbiology and Immunology Laboratory, Wilmer Eye Institute, Baltimore, MD
  • J. Dick
    Department of Pathology, The Johns Hopkins University, Baltimore, MD
  • N. Lee
    The Johns Hopkins University School of Medicine, Baltimore, MD
  • J. Lee
    Ophthalmology, Valued Eye Clinic, Taejon, Republic of Korea
  • E. Donnenfeld
    Ophthalmology, Ophthalmic Consultants of Long Island, Rockville Centre, New York, NY
  • T.P. O'Brien
    Ocular Microbiology and Immunology Laboratory, Wilmer Eye Institute, Baltimore, MD
  • Footnotes
    Commercial Relationships  M. Kim, None; P. Botelho, None; C. Zhang, None; J. Dick, None; N. Lee, None; J. Lee, None; E. Donnenfeld, None; T.P. O'Brien, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 3567. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.–K. Kim, P. Botelho, C. Zhang, J. Dick, N. Lee, J. Lee, E. Donnenfeld, T.P. O'Brien; Comparative Efficacy of Topical Mupirocin With Ciprofloxacin, Gatifloxacin and Vancomycin in the Treatment of Experimental Ciprofloxacin– and Methicillin–Resistant Staphylococcus Aureus Keratitis . Invest. Ophthalmol. Vis. Sci. 2006;47(13):3567.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the comparative efficacy of topical mupirocin with vancomycin, gatifloxacin, and ciprofloxacin against high–level ciprofloxacin–resistant MRSA in vitro and in an animal model of keratitis.

Methods: : In vitro susceptibility testing by E test was conducted to determine the minimal inhibitory concentration (MICs) for mupirocin 20 mg/ml, linezolid 20 mg/ml, vancomycin 31 mg/ml, ciprofloxacin 3 mg/ml, gatifloxacin 3 mg/ml, quinupristin–dalfopristin (Synercid) 3 mg/ml and moxifloxacin 5 mg/ml against a clinical strain of Staphylococcus aureus known to resistant to ciprofloxacin and methicillin (MRSA). Experimental keratitis was induced via intrastromal inoculation of the ciprofloxacin–resistant and MRSA in a rabbit model. Forty–five rabbits were randomly divided into 5 groups and each group was treated hourly for 12 hours with topical 0.9% balanced salt solution, 0.3% ciprofloxacin hydrochloride, 0.3% gatifloxacin, 2% mupirocin and vancomycin (25 mg/mL). Corneas were excised, homogenized and serial dilutions plated in duplicate for incubation. Antibacterial efficacy of each regimen was determined by quantitative bacteriologic analysis after 24 hours at 35°C.

Results: : Mupirocin demonstrated high activity against ciprofloxacin–resistant MRSA in vitro. The ranges of MICs are 0.064 mg/l for mupirocin and 0.094–0.25 mg/l for quinupristin–dalfopristin (Synercid) and 1–1.5 mg/l for vancomycin. Treatment with 0.3% gatifloxacin, 2% mupirocin, and vancomycin (31 mg/mL) reduced the number of MRSA more significantly than the controls and those treated with a 0.3% ciprofloxacin (P<0.05), suggesting equal effectiveness in therapy for ciprofloxacin–resistant MRSA keratitis.

Conclusions: : These results suggest that topical mupirocin can be a potential antibacterial agent for treatment of ciprofloxacin (MIC> 32 mg/l) resistant MRSA keratitis.

Keywords: antibiotics/antifungals/antiparasitics • keratitis • Staphylococcus 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×